In 57 patients with previously treated unresectable biliary tract cancer, atezolizumab plus varlilumab with or without cobimetinib gave rare responses (ORR 0% vs 3.8%) and median PFS 2.40 vs 1.84 months (HR 0.67, 95% CI 0.38–1.18); trial closed early at interim analysis.
RCTn = 57
Heumann et al. A Randomized Phase II Study of Combination Atezolizumab and Varlilumab (CDX-1127) with or without Cobimetinib in Previously Treated Unresectable Biliary Tract Cancer